UK markets closed

Pfizer Stock Dives After Blockbuster Cancer Drug Flops In Late-Stage Test

ALLISON GATLIN
Pfizer Stock Dives After Blockbuster Cancer Drug Flops In Late-Stage Test

Pfizer said its blockbuster drug, Ibrance, failed to make a difference in early-stage breast cancer — leading PFE stock to tumble. Ibrance is already approved in late-stage cancer.